Advertisement
EBS vs SIGA
Which Stock Would AI Choose? Emergent BioSolutions (EBS) vs. SIGA Technologies (SIGA) Stock Comparison
Key Takeaways
- EBS is a diversified biopharmaceutical firm anchored by medical countermeasures (MCM) and the NARCAN naloxone franchise, while SIGA is a more concentrated antiviral specialist built around TPOXX.
- Both companies rely heavily on government and international procurement, but EBS has a broader, more diversified revenue base than SIGA.
- EBS swung to full-year 2025 profitability and expanded margins sharply, even as revenue declined year over year.
- SIGA remains debt-free with a strong cash position but posted a steep fourth-quarter revenue drop and faces European regulatory uncertainty over mpox.
- Relative performance reflects two distinct profiles: an improving turnaround story at EBS versus lumpy, contract-driven earnings at SIGA.
Introduction
Investors in biodefense and public-health names often compare EBS (Emergent BioSolutions) and SIGA (SIGA Technologies) because both generate meaningful revenue from government stockpiling of medical countermeasures against biological threats. Yet the two companies occupy different positions in the sector. Emergent BioSolutions operates a diversified portfolio spanning smallpox, anthrax, and botulism countermeasures plus the NARCAN naloxone franchise, while SIGA Technologies is anchored by a single flagship antiviral, TPOXX. This stock comparison is relevant for traders and investors assessing how market positioning, growth drivers, and recent momentum differ between a recovering diversified biopharma and a focused, cash-rich specialty player.
EBS Overview and Recent Performance
Emergent BioSolutions develops and manufactures medical countermeasures (MCM, or products designed to respond to biological threats) and maintains a market-leading position in naloxone through NARCAN Nasal Spray. In recent weeks, the company has emphasized a multi-year transformation focused on deleveraging, cost discipline, and margin expansion. For full-year 2025, EBS reported total revenue of roughly $743 million, a decline from about $1.04 billion in 2024, but swung to net income of approximately $53 million from a prior-year loss. Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) margin nearly doubled to about 28%, and net leverage improved materially, from roughly 3.3x to about 1.9x.
Recent market activity has been shaped by mixed signals: fourth-quarter revenue came in below analyst expectations, but investors focused on the improving profitability profile and healthy liquidity. The company also secured a series of MCM contract awards and options, expanded international orders, and executed share repurchases and voluntary debt paydown, all of which have supported sentiment around its turnaround narrative.
SIGA Overview and Recent Performance
SIGA Technologies is a commercial-stage pharmaceutical company focused on orthopoxviruses, with its flagship product TPOXX (tecovirimat) approved in the U.S. for the treatment of smallpox. The company's revenue is highly concentrated in government and international procurement, which creates notable quarter-to-quarter variability. For full-year 2025, SIGA reported total revenue of roughly $94.6 million, down from about $138.7 million in 2024, with net income declining to approximately $23.3 million from $59.2 million.
Recent performance has been pressured by a steep fourth-quarter revenue drop and a net loss for that period, as well as European regulatory scrutiny. The European Medicines Agency (EMA) initiated a reassessment of tecovirimat after clinical trials raised questions about its effectiveness against mpox, and the company expects the mpox indication may be withdrawn while smallpox indications are maintained. On a more positive note, SIGA holds a debt-free balance sheet with roughly $172 million in cash, received a $13 million international order for oral TPOXX, and continues to pursue new procurement contracts.
Trending AI Robots
For traders seeking a data-driven edge in this type of stock comparison, Tickeron's Trending AI Robots page offers a curated view of its most relevant automated strategies. Tickeron hosts hundreds of AI trading bots that collectively trade thousands of different tickers, but only those best suited to current market conditions earn a place in this featured section. These bots vary widely in trading style, strategy, timeframe, historical performance, and the specific set of tickers they trade, giving users access to a broad range of statistical profiles and approaches. For example, many bots publish metrics such as win rate, trade frequency, and profit factor, helping traders evaluate consistency and risk. Explore the Trending AI Robots page to see which automated strategies are currently aligned with market conditions.
Head-to-Head Comparison
The clearest contrast between these two names is diversification versus concentration. EBS spans multiple countermeasure categories and a commercial naloxone franchise, which smooths revenue somewhat across products, though it still depends heavily on government contracts. SIGA, by contrast, is largely a single-product story in TPOXX, making its results highly sensitive to procurement timing and regulatory decisions.
Growth drivers also differ. Emergent BioSolutions is focused on margin expansion, debt reduction, and international MCM demand, while SIGA's outlook hinges on securing new U.S. and international TPOXX orders and resolving European regulatory questions. On financial stability, SIGA carries no debt and substantial cash, whereas Emergent has been actively deleveraging from a higher base. Market sentiment reflects these dynamics: Emergent is often viewed through a turnaround lens, while SIGA is seen as a cash-rich but lumpy, contract-dependent operator. Both face headline-driven volatility tied to biosecurity news and government procurement cycles.
Tickeron AI Verdict
Based on observable factors such as trend consistency, stability, catalysts, and relative positioning, Tickeron's AI would likely favor EBS in the current environment. Emergent BioSolutions presents a more consistent improvement trajectory, with expanding margins, falling leverage, and a diversified revenue base that reduces single-contract dependence. SIGA's debt-free balance sheet and cash reserves are strengths, but its concentrated TPOXX franchise and pending European regulatory decision introduce greater near-term uncertainty. That said, both names carry meaningful headline and procurement risk, so any AI-driven preference is probabilistic rather than definitive and should be weighed alongside each company's evolving fundamentals.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EBS is a StrongBuy and SIGA is a Hold.
Aroon Indicator for EBS shows an upward move is likely
EBS's Aroon Indicator triggered a bullish signal on October 14, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 177 similar instances where the Aroon Indicator showed a similar pattern. In 149 of the 177 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
EBS moved above its 50-day moving average on September 16, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for EBS crossed bullishly above the 50-day moving average on September 21, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 69%.
Following a +1.92% 3-day Advance, the price is estimated to grow further. Considering data from situations where EBS advanced for three days, in 208 of 264 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
The 10-day RSI Indicator for EBS moved out of overbought territory on September 18, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 24 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 89%.
The Momentum Indicator moved below the 0 level on October 19, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EBS as a result. In 79 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for EBS turned negative on October 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 39 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EBS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
EBS broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.931) is normal, around the industry mean (11.138). P/E Ratio (-1.824) is within average values for comparable stocks, (-7.600). Projected Growth (PEG Ratio) (0.160) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.038) among similar stocks. P/S Ratio (0.493) is also within normal values, averaging (178.797).
The Tickeron Price Growth Rating for this company is 75 (best 1 - 100 worst), indicating slightly worse than average price growth. EBS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EBS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Momentum Indicator for SIGA turns negative, indicating new downward trend
SIGA saw its Momentum Indicator move below the 0 level on October 09, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 87 similar instances where the indicator turned negative. In 74 of the 87 cases, the stock moved further down in the following days. The odds of a decline are at 85%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for SIGA turned negative on October 08, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 39 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.
SIGA moved below its 50-day moving average on October 19, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SIGA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The 10-day moving average for SIGA crossed bullishly above the 50-day moving average on September 25, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 87%.
Following a +3.57% 3-day Advance, the price is estimated to grow further. Considering data from situations where SIGA advanced for three days, in 234 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
SIGA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 138 of 175 cases where SIGA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 79%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 1 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.356) is normal, around the industry mean (11.138). P/E Ratio (-104.000) is within average values for comparable stocks, (-7.600). Projected Growth (PEG Ratio) (0.020) is also within normal values, averaging (2.152). SIGA's Dividend Yield (0.769) is considerably higher than the industry average of (0.038). P/S Ratio (4.161) is also within normal values, averaging (178.797).
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating fairly steady price growth. SIGA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 91 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SIGA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
EBS | SIGA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 77 | 91 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 42 Fair valued | 1 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 97 | 91 | |
PRICE GROWTH RATING 1..100 | 75 | 63 | |
P/E GROWTH RATING 1..100 | 98 | 100 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SIGA's Valuation (1) in the Pharmaceuticals Other industry is somewhat better than the same rating for EBS (42) in the Biotechnology industry. This means that SIGA’s stock grew somewhat faster than EBS’s over the last 12 months.
SIGA's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as EBS (100) in the Biotechnology industry. This means that SIGA’s stock grew similarly to EBS’s over the last 12 months.
SIGA's SMR Rating (91) in the Pharmaceuticals Other industry is in the same range as EBS (97) in the Biotechnology industry. This means that SIGA’s stock grew similarly to EBS’s over the last 12 months.
SIGA's Price Growth Rating (63) in the Pharmaceuticals Other industry is in the same range as EBS (75) in the Biotechnology industry. This means that SIGA’s stock grew similarly to EBS’s over the last 12 months.
EBS's P/E Growth Rating (98) in the Biotechnology industry is in the same range as SIGA (100) in the Pharmaceuticals Other industry. This means that EBS’s stock grew similarly to SIGA’s over the last 12 months.
| EBS | SIGA | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 89% | N/A |
| Stochastic ODDS (%) | 2 days ago 83% | 2 days ago 75% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 85% |
| MACD ODDS (%) | 2 days ago 85% | 2 days ago 81% |
| TrendWeek ODDS (%) | 2 days ago 87% | 2 days ago 79% |
| TrendMonth ODDS (%) | 2 days ago 87% | 2 days ago 80% |
| Advances ODDS (%) | 24 days ago 79% | 8 days ago 80% |
| Declines ODDS (%) | 2 days ago 86% | 4 days ago 75% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 72% |
| Aroon ODDS (%) | 2 days ago 84% | 2 days ago 79% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
EBS’s FA Score shows that 0 FA rating(s) are green while SIGA’s FA Score has 1 green FA rating(s).
- EBS’s FA Score: 0 green, 5 red.
- SIGA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
EBS’s TA Score shows that 5 TA indicator(s) are bullish while SIGA’s TA Score has 5 bullish TA indicator(s).
- EBS’s TA Score: 5 bullish, 5 bearish.
- SIGA’s TA Score: 5 bullish, 4 bearish.
Price Growth
EBS (@Pharmaceuticals: Generic) experienced а -10.27% price change this week, while SIGA (@Pharmaceuticals: Generic) price change was +0.65% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -2.94%. For the same industry, the average monthly price growth was -9.84%, and the average quarterly price growth was +9.53%.
Reported Earning Dates
EBS is expected to report earnings on Nov 02, 2026.
SIGA is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (-2.94% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
EBS and
Correlation & Price change
A.I.dvisor indicates that over the last year, EBS has been loosely correlated with SIGA. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if EBS jumps, then SIGA could also see price increases.
| Ticker / NAME | Correlation To EBS | 1D Price Change % | ||
|---|---|---|---|---|
| EBS | 100% | -1.43% | ||
| SIGA - EBS | 40% Loosely correlated | -0.95% | ||
| COLL - EBS | 40% Loosely correlated | -1.36% | ||
| AMPH - EBS | 37% Loosely correlated | +1.00% | ||
| XERS - EBS | 33% Loosely correlated | -3.10% | ||
| VTRS - EBS | 32% Poorly correlated | -1.07% | ||
More | ||||
SIGA and
Correlation & Price change
A.I.dvisor tells us that SIGA and EBS have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SIGA and EBS's prices will move in lockstep.
| Ticker / NAME | Correlation To SIGA | 1D Price Change % | ||
|---|---|---|---|---|
| SIGA | 100% | -0.95% | ||
| EBS - SIGA | 33% Poorly correlated | -1.43% | ||
| ETON - SIGA | 29% Poorly correlated | -1.77% | ||
| AYTU - SIGA | 28% Poorly correlated | -2.49% | ||
| AMRX - SIGA | 27% Poorly correlated | +1.81% | ||
| SBFM - SIGA | 25% Poorly correlated | -2.09% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| IBLC | 40.08 | 1.44 | +3.73% |
| iShares Blockchain and Tech ETF (IBLC) | |||
| QDTE | 28.45 | 0.32 | +1.14% |
| Roundhill Nasdaq-100 0DTE Covered Call Strategy ETF (QDTE) | |||
| XLI | 168.31 | 1.51 | +0.91% |
| State Street Industrial Select Sector SPDR ETF (XLI) | |||
| XTWY | 34.39 | 0.08 | +0.23% |
| BondBloxx Bloomberg Twenty Year Target Duration US Treasury ETF (XTWY) | |||
| MRGR | 45.51 | N/A | N/A |
| ProShares Merger ETF (MRGR) | |||